A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Abstract Background This double-blind, randomized, 78-week study evaluated the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of PF-06410293, a candidate adalimumab biosimilar, versus adalimumab reference product (Humira®) sourced from the EU (adalimumab-EU) in biologic-naï...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Roy M. Fleischmann, Rieke Alten, Margarita Pileckyte, Kasia Lobello, Steven Y. Hua, Carol Cronenberger, Daniel Alvarez, Amy E. Bock, K. Lea Sewell
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: BMC 2018-08-01
Sarja:Arthritis Research & Therapy
Aiheet:
Rheumatoid arthritis
Adalimumab
Biosimilar
Comparative clinical study
Linkit:http://link.springer.com/article/10.1186/s13075-018-1676-y

Internet

http://link.springer.com/article/10.1186/s13075-018-1676-y

Samankaltaisia teoksia